Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | THAR |
---|---|---|
09:32 ET | 4691 | 2.62 |
09:33 ET | 300 | 2.57 |
09:39 ET | 100 | 2.57 |
09:46 ET | 500 | 2.57 |
09:50 ET | 2600 | 2.46 |
10:04 ET | 121 | 2.5331 |
10:18 ET | 195 | 2.5541 |
10:26 ET | 135 | 2.5003 |
10:31 ET | 1763 | 2.51 |
10:33 ET | 400 | 2.51 |
10:40 ET | 140 | 2.52 |
10:47 ET | 1100 | 2.59 |
10:49 ET | 200 | 2.59 |
10:58 ET | 4919 | 2.585 |
11:00 ET | 6692 | 2.6291 |
11:02 ET | 1200 | 2.63 |
11:03 ET | 4709 | 2.66 |
11:05 ET | 2100 | 2.65 |
11:12 ET | 2100 | 2.64 |
11:20 ET | 1200 | 2.65 |
11:21 ET | 3170 | 2.67 |
11:23 ET | 4118 | 2.63 |
11:25 ET | 900 | 2.62 |
11:32 ET | 200 | 2.6 |
11:34 ET | 494 | 2.6 |
11:38 ET | 1000 | 2.5988 |
12:26 ET | 200 | 2.62 |
12:37 ET | 2488 | 2.62 |
12:39 ET | 200 | 2.62 |
12:42 ET | 7931 | 2.6392 |
12:44 ET | 2100 | 2.66 |
12:46 ET | 3999 | 2.69 |
12:53 ET | 11610 | 2.68 |
12:55 ET | 5558 | 2.65 |
12:57 ET | 1063 | 2.655 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Tharimmune Inc | 3.9M | -0.1x | --- |
Polyrizon Ltd | 3.9M | -3.9x | --- |
Avenue Therapeutics Inc | 3.8M | -0.2x | --- |
Cyclerion Therapeutics Inc | 3.8M | -0.7x | --- |
TNF Pharmaceuticals Inc | 3.7M | -0.2x | --- |
Pasithea Therapeutics Corp | 4.0M | -0.2x | --- |
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-18.44 |
Book Value | $11.67 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.